Home▸Acne & Skin Barrier Treatment▸Isotretinoin Teratogenicity Risk Management (iPLEDGE) Simulator

🧴 Isotretinoin Teratogenicity Risk Management (iPLEDGE) Simulator

This simulation is designed to manage the teratogenic risks associated with isotretinoin use, particularly for women of childbearing age. It explains the iPLEDGE program’s requirements and guidelines to ensure safe and effective treatment while minimizing potential harm to developing fetuses.

Acne & Skin Barrier Treatment2DModerate60 FPS
isotretinoin-ipledge-teratogenicity-simulator ↗ Open standalone

Assessing Candidacy Before Isotretinoin Therapy Begins

Short placeholder: severe acne patient screened for pregnancy potential first.

  • High: Teratogenic risk (placeholder caption text here)
  • 1st: Screening step (placeholder caption text here)
  • CBP: Population affected (placeholder caption text here)
  • iPLEDGE: Program name (placeholder caption text here)

Why candidacy screening matters

Placeholder body text, short and generic, five to twelve words per line.

Placeholder line two, kept intentionally brief here.

Placeholder line three, same short placeholder style.

iPLEDGE Enrollment and Dual Contraception Counseling

Short placeholder: patient education plus two contraception methods required.

  • 2: Contraception methods (placeholder caption text here)
  • Multiple: Education topics (placeholder caption text here)
  • REMS: Registry (placeholder caption text here)
  • Required: Consent forms (placeholder caption text here)

Enrollment requirements overview

Placeholder body text, short and generic, five to twelve words per line.

Placeholder line two, kept intentionally brief here.

Placeholder line three, same short placeholder style.

The Monthly Pregnancy Test Verification Cycle

Short placeholder: negative test required in-window before each refill.

  • 7 days: Test window (placeholder caption text here)
  • Lab/office: Verification (placeholder caption text here)
  • Monthly: Cycle frequency (placeholder caption text here)
  • Test-linked: Refill gate (placeholder caption text here)

How the verification loop works

Placeholder body text, short and generic, five to twelve words per line.

Placeholder line two, kept intentionally brief here.

Placeholder line three, same short placeholder style.

Ongoing Monitoring Across the Full Treatment Course

Short placeholder: 30-day supply caps enforce monthly prescriber check-ins.

  • 5-6 mo: Course length (placeholder caption text here)
  • 30 days: Max supply (placeholder caption text here)
  • Monthly: Prescriber visits (placeholder caption text here)
  • Ongoing: Adherence checks (placeholder caption text here)

Monitoring cadence details

Placeholder body text, short and generic, five to twelve words per line.

Placeholder line two, kept intentionally brief here.

Placeholder line three, same short placeholder style.

Program Outcomes — Exposed Pregnancy Rate Reduction

Short placeholder: monthly checks cut exposed pregnancies, not eliminated.

  • Higher: Pre-program rate (placeholder caption text here)
  • Lower: iPLEDGE-era rate (placeholder caption text here)
  • Nonzero: Residual risk (placeholder caption text here)
  • Ongoing: Program status (placeholder caption text here)

What the outcome data shows

Placeholder body text, short and generic, five to twelve words per line.

Placeholder line two, kept intentionally brief here.

Placeholder highlight callout, short and specific, under twelve words.
⚙ Under the hood

This simulation is designed to manage the teratogenic risks associated with isotretinoin use, particularly for women of childbearing age. It explains the iPLEDGE program’s requirements and guidelines to ensure safe and effective treatment while minimizing potential harm to developing fetuses.

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install

What did you find?

Add reproduction steps (optional)